John Lee, MD
Cardiovascular Disease · Kansas City, MONPI 1548214158
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 95.3% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $9,188, more than ten times the $46 reported in 2019.
Across 13 payments — averaging $757.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Biosense Webster, Inc.$147
- Cardiva Medical, Inc.$119
- Endologix LLC$119
- Johnson & Johnson$47
- Cook Medical LLC$24
- plus $11 from 1 others
Across 28 payments — averaging $1290.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$35K
- Regeneron$1K
What the payments were for
- Consulting fees$5,25053%
- Travel & lodging$3,79138%
- Food & beverage$8098%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 7 | $9,383 |
| Biosense Webster, Inc. | 1 | $147 |
| Cardiva Medical, Inc. | 1 | $119 |
| Endologix LLC | 1 | $119 |
| Johnson & Johnson | 1 | $47 |
| Cook Medical LLC | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,850 in reported general payments places this provider in the 75th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 389 | $436,234 |
| EntrestoSacubitril/Valsartan | 72 | $99,183 |
| XareltoRivaroxaban | 71 | $90,316 |
| JardianceEmpagliflozin | 52 | $76,750 |
| Droxidopa | 59 | $75,962 |
| Repatha SureclickEvolocumab | 28 | $28,030 |
| Midodrine Hcl | 233 | $22,285 |
| FarxigaDapagliflozin Propanediol | 15 | $14,016 |
| CorlanorIvabradine Hcl | 13 | $13,354 |
| Repatha SyringeEvolocumab | 12 | $11,352 |
| Pyridostigmine Bromide | 125 | $9,810 |
| BrilintaTicagrelor | 16 | $9,412 |
| Dofetilide | 68 | $6,412 |
| Propafenone Hcl ErPropafenone Hcl | 29 | $6,123 |
| Flecainide Acetate | 114 | $5,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $47 | $90,31671 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Kansas City
- Mikhail KosiborodKansas City$1.1M
- John SpertusKansas City$360K
- Kyle LehenbauerKansas City$108K
- Deepa UpadhyayaKansas City$58K
- David SkolnickKansas City$44K
- Garth GrahamKansas City$32K
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- James FairlambColumbia$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.